



Friday, 3 September 2010

## **PRESS RELEASE**

### **IMPEDIMED ANNOUNCES TWO MORE MANAGED CARE CONTRACTS FOR L-DEX® TESTING ADVANCING U.S. REIMBURSEMENT**

ImpediMed Limited today announced two additional contracts with U.S. managed care organisations for use of its L-Dex technology as an aid in the clinical assessment of lymphoedema in female breast cancer patients. Encore Health Network and Three Rivers Provider Network are Preferred Provider Organizations (PPOs) under contract with major U.S. healthcare insurers to provide healthcare services. Combined, these PPOs contract with healthcare providers to provide services to over 10 million members.

“With so many payers and providers in the U.S. healthcare system, each contract with managed care organisations and each coverage statement with health insurers, builds towards effective reimbursement for L-Dex testing in the U.S. market”, said Greg Brown, ImpediMed’s CEO. “Encore Health Network is focused in the Midwest U.S. states while Three Rivers Provider Network is a national U.S. network.”

Across the United States, ImpediMed is continuing discussions with a variety of managed care organisations, public and private health insurance providers and contracted provider networks to provide medical services. This includes working with Independent Physician Associations (IPA’s), Health Maintenance Organizations (HMO’s) and medical groups.

#### **ENDS**

**For further information contact:**

**Greg Brown                      ImpediMed CEO**

**T: 61-7-3860-3700**

**Mobile/Cell: +61408281127**

L-Dex® is a trademark of ImpediMed Limited.

“L-Dex® values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

## **About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit. [www.impedimed.com](http://www.impedimed.com)

## **About US Managed Care**

For more information, visit. <http://www.americanheart.org/presenter.jhtml?identifier=4663>  
& <http://www.nlm.nih.gov/medlineplus/managedcare.html>

For personal use only